Type I interferons (IFNs) signal by forming a high affinity IFN-IFNAR2 dimer, which subsequently recruits IFNAR1 to form a ternary complex that initiates JAK/STAT signaling. Among the 12 IFNα subtypes, IFNα1 has a uniquely low affinity for IFNAR2 (<100 × of the other IFNα subtypes) and commensurately weak antiviral activity, suggesting an undefined function distinct from suppression of viral infections. Also unique in IFNα1 is substitution of a serine for phenylalanine at position 27, a contact point that stabilizes the IFNα:IFNAR2 hydrophobic interface. To determine whether IFNα1-S27 contributes to the low affinity for IFNAR2, we created an IFNα1 mutein, IFNα1-S27F, and compared it to wild-type IFNα1 and IFNα2. Substitution of phenylalanine for serine increased affinity for IFNAR2 ∼4-fold and commensurately enhanced activation of STAT1, STAT3, and STAT5, transcription of a subset of interferon stimulated genes, and restriction of vesicular stomatitis virus infection in vitro. Structural modeling suggests that S27 of IFNα1 disrupts the IFNα:IFNAR2 hydrophobic interface that is otherwise stabilized by F27 and that replacing S27 with phenylalanine partially restores the hydrophobic surface. Disruption of the hydrophobic IFNα:IFNAR2 interface by the unique S27 of IFN α1 contributes to its low affinity and weak antiviral activity.
Get full access to this article
View all access options for this article.
References
1.
de WeerdNA, VivianJP, NguyenTK, ManganNE, GouldJA, BraniffSJ, Zaker-TabriziL, FungKY, ForsterSC, BeddoeT, ReidHH, RossjohnJ, HertzogPJ. 2013. Structural basis of a unique interferon-beta signaling axis mediated via the receptor IFNAR1. Nat Immunol, 14(9):901–907.
2.
FishEN, BanerjeeK, StebbingN. 1983. Human leukocyte interferon subtypes have different antiproliferative and antiviral activities on human cells. Biochem Biophys Res Commun, 112(2):537–546.
3.
GeninP, LinR, HiscottJ, CivasA. 2009a. Differential regulation of human interferon A gene expression by interferon regulatory factors 3 and 7. Mol Cell Biol, 29(12):3435–3450.
4.
GeninP, VaccaroA, CivasA. 2009b. The role of differential expression of human interferon—a genes in antiviral immunity. Cytokine Growth Factor Rev, 20(4):283–295.
5.
HarrisBD, SchreiterJ, ChevrierM, JordanJL, WalterMR. 2018. Human interferon- and interferon-kappa exhibit low potency and low affinity for cell-surface IFNAR and the poxvirus antagonist B18R. J Biol Chem, 293:16057–16068.
6.
HillyerP, ManeVP, ChenA, Dos SantosMB, SchrammLM, ShepardRE, LuongoC, Le NouenC, HuangL, YanL, BuchholzUJ, JubinRG, CollinsPL, RabinRL. 2017. Respiratory syncytial virus infection induces a subset of types I and III interferons in human dendritic cells. Virology, 504:63–72.
7.
HillyerP, ManeVP, SchrammLM, PuigM, VerthelyiD, ChenA, ZhaoZ, NavarroMB, KirschmanKD, BykadiS, JubinRG, RabinRL. 2012. Expression profiles of human interferon-alpha and interferon-lambda subtypes are ligand- and cell-dependent. Immunol Cell Biol, 90(8):774–783.
8.
JaksE, GavutisM, UzeG, MartalJ, PiehlerJ. 2007. Differential receptor subunit affinities of type I interferons govern differential signal activation. J Mol Biol, 366(2):525–539.
9.
JohnstonMJ, NemrK, HeffordMA. 2010. Influence of bovine serum albumin on the secondary structure of interferon alpha 2b as determined by far UV circular dichroism spectropolarimetry. Biologicals, 38(2):314–320.
10.
KalieE, JaitinDA, AbramovichR, SchreiberG. 2007. An interferon alpha2 mutant optimized by phage display for IFNAR1 binding confers specifically enhanced antitumor activities. J Biol Chem, 282(15):11602–11611.
11.
KalieE, JaitinDA, PodoplelovaY, PiehlerJ, SchreiberG. 2008. The stability of the ternary interferon-receptor complex rather than the affinity to the individual subunits dictates differential biological activities. J Biol Chem, 283(47):32925–32936.
12.
KeY, ReddelRR, GerwinBI, MiyashitaM, McMenaminM, LechnerJF, HarrisCC. 1988. Human bronchial epithelial cells with integrated SV40 virus T antigen genes retain the ability to undergo squamous differentiation. Differentiation, 38(1):60–66.
13.
KimuraT, JiangS, NishizawaM, YoshigaiE, HashimotoI, NishikawaM, OkumuraT, YamadaH. 2013. Stabilization of human interferon-alpha1 mRNA by its antisense RNA. Cell Mol Life Sci, 70(8):1451–1467.
LavoieTB, KalieE, Crisafulli-CabatuS, AbramovichR, DiGioiaG, MoolchanK, PestkaS, SchreiberG. 2011. Binding and activity of all human alpha interferon subtypes. Cytokine, 56(2):282–289.
16.
MarijanovicZ, RagimbeauJ, van der HeydenJ., UzeG, PellegriniS.2007. Comparable potency of IFNalpha2 and IFNbeta on immediate JAK/STAT activation but differential down-regulation of IFNAR2. Biochem J, 407(1):141–151.
17.
OuyangS, GongB, LiJZ, ZhaoLX, WuW, ZhangFS, SunL, WangSJ, PanM, LiC, LiangW, ShawN, ZhengJ, ZhaoGP, WangY, LiuZJ, LiangM. 2012. Structural insights into a human anti-IFN antibody exerting therapeutic potential for systemic lupus erythematosus. J Mol Med, 90(7):837–846.
18.
ReddelRR, KeY, KaighnME, Malan-ShibleyL, LechnerJF, RhimJS, HarrisCC. 1988. Human bronchial epithelial cells neoplastically transformed by v-Ki-ras: altered response to inducers of terminal squamous differentiation. Oncogene Res, 3(4):401–408.
19.
SchreiberG.2017. The molecular basis for differential type I interferon signaling. J Biol Chem, 292:7285–7294.
20.
SchreiberG, PiehlerJ. 2015. The molecular basis for functional plasticity in type I interferon signaling. Trends Immunol, 36(3):139–149.
21.
StifterSA, MatthewsAY, ManganNE, FungKY, DrewA, TateMD, Soares da CostaTP, HampseyD, MayallJ, HansbroPM, Garcia MinambresA, EidSG, MakJ, ScobleJ, LovreczG, deWeerdNA, HertzogPJ. 2018. Defining the distinct, intrinsic properties of the novel type I interferon, IFN. J Biol Chem, 293(9):3168–3179.
22.
ThomasC, MoragaI, LevinD, KrutzikPO, PodoplelovaY, TrejoA, LeeC, YardenG, VleckSE, GlennJS, NolanGP, PiehlerJ, SchreiberG, GarciaKC. 2011. Structural linkage between ligand discrimination and receptor activation by type I interferons. Cell, 146(4):621–632.
23.
WalterMR.1997. Three-dimensional models of interferon-alpha subtypes IFN-con1, IFN-alpha8, andIFN-alpha1 derived from the crystal structure of IFN-alpha2b. Semin Oncol, 24(3 Suppl 9):S9-52-S59–S62.
24.
ZaritskyLA, BedsaulJR, ZoonKC. 2015. Virus Multiplicity of Infection Affects Type I Interferon Subtype Induction Profiles and Interferon-Stimulated Genes. J Virol, 89(22):11534–11548.
25.
ZhangJ, LiangY, ZhangY. 2011. Atomic-level protein structure refinement using fragment-guided molecular dynamics conformation sampling. Structure, 19(12):1784–1795.
26.
ZhangKJ, YinXF, YangYQ, LiHL, XuYN, ChenLY, LiuXJ, YuanSJ, FangXL, XiaoJ, WuS, XuHN, ChuL, KatlinskiKV, KatlinskayaYV, GuoRB, WeiGW, WangDC, LiuXY, FuchsSY. 2017. A Potent In Vivo Antitumor Efficacy of Novel Recombinant Type I Interferon. Clin Cancer Res, 23(8):2038–2049.
